-
Mindray Launches First Wireless Handheld Ultrasound System, TE Air
•
China-based medical device firm Mindray (SHE: 300760) has announced the market launch of the firm’s first wireless handheld ultrasound system, branded TE Air. This innovative device represents a historic breakthrough in image quality, integrating professional-level imaging into a compact and lightweight wireless system for ease of use in various medical…
-
Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development
•
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced a licensing agreement with US firm Cullinan Oncology, Inc. The deal grants Cullinan exclusive rights to develop and commercialize HBM7008 in the United States (including the District of Columbia and Puerto Rico). This…
-
Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment in a Phase I clinical study for its tetravalent influenza virus split vaccine. This marks a significant step in the development of a vaccine designed to provide broader protection against influenza, particularly for individuals aged…
-
Jiangsu Recbio Completes First Tranche Enrollment for Shingles Vaccine REC610
•
China-based Jiangsu Recbio Technology Co., Ltd has announced the completion of the first tranche of subject enrollment in a clinical study for its novel adjuvanted recombinant shingles vaccine, REC610. This milestone marks a significant step in the development of a vaccine designed to provide enhanced protection against shingles, particularly for…
-
Beijing Wantai Initiates Phase I Study for 20-Valent Pneumonia Vaccine
•
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation and first subject enrollment in a Phase I clinical study for its 20-valent pneumonia vaccine. This marks a significant step in the development of a vaccine designed to provide broader protection against pneumonia. Vaccine Development and…
-
Gracell Biotechnologies Gains IND Approval for GC012F in China
•
Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) for its chimeric antigen receptor (CAR) T cell candidate GC012F. The dual BCMA/CD19-targeted therapy is set to be assessed in treating relapsed/refractory multiple myeloma (r/r MM), marking a significant step in the development…
-
China’s Ministries Release Plan for Urban Medical Group Pilots
•
A group of ministries led by the National Health Commission (NHC), including the National Development and Reform Commission (NDRC), Ministry of Finance, Ministry of Human Resources and Social Security, National Administration of Traditional Chinese Medicine, and National Bureau of Disease Control and Prevention, have jointly released a work plan for…
-
ThinmedTech Partners with West China Hospital for CKD Digital Therapy
•
ThinmedTech, a chronic disease clinical management solution provider based in Chongqing, has struck a partnership with West China Hospital. The collaboration aims to work together on medical research and product transformation in the area of “chronic kidney disease (CKD) sodium restriction digital therapy.” This partnership marks a significant step in…
